Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened ...

Given this risk, we thought we'd take a look at whether Dianthus Therapeutics (NASDAQ:DNTH) shareholders should be worried about its cash burn. For the purposes of this article, c ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago. These ...

Reports Q4 revenue $1.33M, consensus $859,700. “We remain on track to report top-line data in 2H’25 from our Phase 2 clinical trial of DNTH103 ...

TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 a.m. ET and host one-on-one meetings with ...

TD Cowen initiated coverage of Dianthus (DNTH) with a Buy rating and no price target The firm says DNTH103 is “highly potent” and selectively targets classical pathway while preserving lectin ...

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Option Chain is currently not available. Nasdaq provides call and put options information of stocks. Financial analysts and individual investors can rely on the chain to gauge the stock's ...